{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:41:32Z","timestamp":1787503292054,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatric.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Geriatric Medicine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.cger.2025.01.001","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T07:26:19Z","timestamp":1741073179000},"page":"153-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overactive Bladder Medications in Geriatrics\u2014Risks and Realities"],"prefix":"10.1016","volume":"41","author":[{"given":"Tyler","family":"Trump","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard B.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cger.2025.01.001_bib1","article-title":"The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder","volume":"15","author":"Cameron","year":"2024","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"10.1016\/j.cger.2025.01.001_bib2","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","article-title":"National community prevalence of overactive bladder in the United States stratified by sex and age","volume":"77","author":"Coyne","year":"2011","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.cger.2025.01.001_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2022.01.045","article-title":"European Association of Urology Guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. part 1: diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence","volume":"82","author":"Nambiar","year":"2022","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.cger.2025.01.001_bib4","doi-asserted-by":"crossref","first-page":"E142","DOI":"10.5489\/cuaj.4586","article-title":"CUA guideline on adult overactive bladder","volume":"11","author":"Corcos","year":"2017","journal-title":"Can Urol Assoc J"},{"issue":"7","key":"10.1016\/j.cger.2025.01.001_bib5","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"71","year":"2023","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.cger.2025.01.001_bib6","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s40266-021-00901-2","article-title":"A\u00a012-Year retrospective study of the prevalence of anticholinergic polypharmacy and Associated Outcomes among Medicare patients with overactive bladder in the USA","volume":"38","author":"Campbell","year":"2021","journal-title":"Drugs Aging"},{"issue":"5","key":"10.1016\/j.cger.2025.01.001_bib7","doi-asserted-by":"crossref","first-page":"e2315074","DOI":"10.1001\/jamanetworkopen.2023.15074","article-title":"Inequities in filled overactive bladder medication prescriptions in the US","volume":"6","author":"Luchristt","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cger.2025.01.001_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.urology.2023.11.033","article-title":"Oxybutynin-associated cognitive impairment: evidence and implications for overactive bladder treatment","volume":"186","author":"Chancellor","year":"2024","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.cger.2025.01.001_bib9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.cger.2025.01.001_bib10","first-page":"CD003781","article-title":"Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults","author":"Stoniute","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cger.2025.01.001_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/iju.12298","article-title":"Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study","volume":"21","author":"Akino","year":"2014","journal-title":"Int J Urol"},{"key":"10.1016\/j.cger.2025.01.001_bib12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40266-017-0474-6","article-title":"Older people\u2019s preferences for side effects associated with antimuscarinic treatments of overactive bladder: a discrete-choice experiment","volume":"34","author":"Decalf","year":"2017","journal-title":"Drugs Aging"},{"issue":"3","key":"10.1016\/j.cger.2025.01.001_bib13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1570159X11311030006","article-title":"Acetylcholinesterase inhibitors: pharmacology and toxicology","volume":"11","author":"Colovi\u0107","year":"2013","journal-title":"Curr Neuropharmacol"},{"issue":"11","key":"10.1016\/j.cger.2025.01.001_bib14","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41585-021-00504-x","article-title":"The cognitive effect of anticholinergics for patients with overactive bladder","volume":"18","author":"Welk","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"6","key":"10.1016\/j.cger.2025.01.001_bib15","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","article-title":"Alzheimer\u2019s disease neuroimaging initiative. association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults","volume":"73","author":"Risacher","year":"2016","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.cger.2025.01.001_bib16","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia: a nested case-control study","volume":"179","author":"Coupland","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cger.2025.01.001_bib17","article-title":"Anticholinergic drugs and risk of dementia: case-control study","volume":"361","author":"Richardson","year":"2018","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.cger.2025.01.001_bib18","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/ageing\/afaa090","article-title":"Anticholinergic drugs and incident dementia, mild cognitive impairment and cognitive decline: a meta-analysis","volume":"49","author":"Pieper","year":"2020","journal-title":"Age Ageing"},{"issue":"2","key":"10.1016\/j.cger.2025.01.001_bib19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.eururo.2006.03.057","article-title":"Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects","volume":"50","author":"Kay","year":"2006","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.cger.2025.01.001_bib20","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/00912700122010528","article-title":"Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system","volume":"41","author":"Todorova","year":"2001","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.cger.2025.01.001_bib21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12877-020-1474-7","article-title":"Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)","volume":"20","author":"Griebling","year":"2020","journal-title":"BMC Geriatr"},{"issue":"1","key":"10.1016\/j.cger.2025.01.001_bib22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/bju.15040","article-title":"Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study","volume":"126","author":"Welk","year":"2020","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.cger.2025.01.001_bib23","first-page":"863","article-title":"Dementia associated with anticholinergic drugs used for overactive bladder: a nested case-control study using the French national medical-administrative database","volume":"208","author":"Malcher","year":"2022","journal-title":"J\u00a0Urol"},{"issue":"9","key":"10.1016\/j.cger.2025.01.001_bib24","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1742-1241.2010.02433.x","article-title":"Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder","volume":"64","author":"Staskin","year":"2010","journal-title":"Int J Clin Pract"},{"issue":"3","key":"10.1016\/j.cger.2025.01.001_bib25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00228-019-02795-x","article-title":"Association between anticholinergic drug burden and mortality in older people: a systematic review","volume":"76","author":"Ali","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.cger.2025.01.001_bib26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bcp.12617","article-title":"Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis","volume":"80","author":"Ruxton","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cger.2025.01.001_bib27","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s12325-018-0796-8","article-title":"The association between overactive bladder and falls and fractures: a systematic review","volume":"35","author":"Szabo","year":"2018","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.cger.2025.01.001_bib28","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/nau.24827","article-title":"The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications","volume":"41","author":"Welk","year":"2022","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.cger.2025.01.001_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026391","article-title":"Association between cumulative anticholinergic burden and falls and fractures inpatients with overactive bladder: US-based retrospective cohort study","volume":"9","author":"Szabo","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.cger.2025.01.001_bib30","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40266-019-00694-5","article-title":"The relationship between anticholinergic exposure and falls, fractures, and mortality in patients with overactive bladder","volume":"36","author":"Suehs","year":"2019","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.cger.2025.01.001_bib31","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.euf.2022.08.002","article-title":"The differential risk of mortality among users of overactive bladder anticholinergic medications and \u03b23 agonists","volume":"9","author":"Welk","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"8","key":"10.1016\/j.cger.2025.01.001_bib32","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s40264-021-01095-7","article-title":"Mirabegron PMR-PASS study group. cardiovascular risk in users of mirabegron compared with users of antimuscarinic treatments for overactive bladder: findings from a non-interventional, multinational, cohort Study","volume":"44","author":"Hoffman","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.cger.2025.01.001_bib33","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1007\/s11606-020-05634-3","article-title":"Risk of mortality associated with non-selective antimuscarinic medications in older adults with dementia: a retrospective study","volume":"35","author":"Kachru","year":"2020","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.cger.2025.01.001_bib34","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/phar.2121","article-title":"Variation in cardiovascular risk related to individual antimuscarinic drugs used to treat overactive bladder: a UK cohort study","volume":"38","author":"Arana","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1016\/j.cger.2025.01.001_bib35","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/j.jamda.2021.08.011","article-title":"Centrally acting anticholinergic drugs used for urinary conditions associated with worse outcomes in dementia","volume":"22","author":"Bishara","year":"2021","journal-title":"J\u00a0Am Med Dir Assoc"},{"issue":"4","key":"10.1016\/j.cger.2025.01.001_bib36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/1074248408325404","article-title":"Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants\u00a0> or\u00a0= 50 years","volume":"13","author":"Olshansky","year":"2008","journal-title":"J\u00a0Cardiovasc Pharmacol Therapeut"},{"issue":"6","key":"10.1016\/j.cger.2025.01.001_bib37","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3390\/medicina58060825","article-title":"Impact of mirabegron administration on the blood pressure and pulse rate in patients with overactive bladder","volume":"58","author":"Ito","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"7","key":"10.1016\/j.cger.2025.01.001_bib38","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009120","article-title":"Hemodynamic effects of cyclic guanosine monophosphate-dependent signaling through \u03b23 adrenoceptor stimulation in patients with advanced heart failure: a randomized invasive clinical trial","volume":"15","author":"Bundgaard","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.cger.2025.01.001_bib39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/SPV.0000000000001008","article-title":"Clinical Consensus Statement: association of anticholinergic medication use and cognition in women with overactive bladder","volume":"27","year":"2021","journal-title":"Female Pelvic Med Reconstr Surg"},{"issue":"8","key":"10.1016\/j.cger.2025.01.001_bib40","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/nau.25037","article-title":"SUFU white paper on overactive bladder anticholinergic medications and dementia risk","volume":"41","author":"Zillioux","year":"2022","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"10.1016\/j.cger.2025.01.001_bib41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13195-024-01530-8","article-title":"Impact of cumulative exposure to anticholinergic and sedative drugs on cognition in older adults: a memory clinic cohort study","volume":"16","author":"Reallon","year":"2024","journal-title":"Alzheimers Res Ther"}],"container-title":["Clinics in Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069025000011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069025000011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T23:44:32Z","timestamp":1752623072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749069025000011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0749069025000011"],"URL":"https:\/\/doi.org\/10.1016\/j.cger.2025.01.001","relation":{},"ISSN":["0749-0690"],"issn-type":[{"value":"0749-0690","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overactive Bladder Medications in Geriatrics\u2014Risks and Realities","name":"articletitle","label":"Article Title"},{"value":"Clinics in Geriatric Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cger.2025.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}